Profound Medical (NASDAQ: PROF) shares unaudited Q2 and H1 2025 results

Rhea-AI Filing Summary

Profound Medical Corp. furnished an update on its recent performance by reporting that it issued a press release with unaudited financial results for the three- and six-month periods ended June 30, 2025. The company also used the release to provide a broader business update.

The press release is attached as Exhibit 99.1 and is furnished, not filed, meaning it is not automatically subject to certain Exchange Act liabilities or incorporated into other securities filings unless specifically referenced. This 8-K is a disclosure vehicle pointing investors to that detailed financial and operational information.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

False000162880800016288082025-08-142025-08-14iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  August 14, 2025

_______________________________

PROFOUND MEDICAL CORP.

(Exact name of registrant as specified in its charter)

_______________________________

Ontario, Canada	001-39032	Not Applicable
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

2400 Skymark Avenue, Unit 6

Mississauga, Ontario, Canada L4W 5K5

(Address of Principal Executive Offices) (Zip Code)

Registrant's Telephone Number, Including Area Code: 647-476-1350

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Shares	PROF	The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

       On August 14, 2025, the Company issued a press release to announce its unaudited financial results for the three and six months ended June 30, 2025 and provided a business update. A copy of the press release is furnished as Exhibit 99.1. 

       The information in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section, and shall not be deemed to be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release dated August 14, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PROFOUND MEDICAL CORP.
Date: August 14, 2025	By:	/s/ Rashed Dewan
		Rashed Dewan
		Chief Financial Officer

FAQ

What did Profound Medical Corp. (PROF) disclose in this 8-K?

Profound Medical Corp. disclosed that it issued a press release announcing unaudited financial results for the three and six months ended June 30, 2025, and provided a business update, with the full release attached as Exhibit 99.1 for more detailed information.

Which period’s results does Profound Medical Corp. (PROF) address in the press release?

The press release addresses Profound Medical Corp.’s unaudited financial results for the three- and six-month periods ended June 30, 2025. These periods cover the company’s second-quarter and first-half performance, along with an accompanying business update for investors and stakeholders.

Is Profound Medical Corp.’s Exhibit 99.1 in this 8-K considered filed with the SEC?

The company states that Item 2.02 information, including Exhibit 99.1, is furnished rather than filed. As a result, it is not automatically subject to Section 18 Exchange Act liabilities or incorporated into other filings unless expressly referenced by the company.

What exhibits are included with Profound Medical Corp.’s (PROF) 8-K?

The 8-K includes Exhibit 99.1, which is the press release dated August 14, 2025, containing unaudited financial results and a business update. It also lists Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.

Who signed the Profound Medical Corp. (PROF) 8-K reporting the June 30, 2025 results?

The 8-K was signed on behalf of Profound Medical Corp. by Rashed Dewan, the company’s Chief Financial Officer. His signature indicates he is the duly authorized officer responsible for submitting this current report under the Securities Exchange Act of 1934.